Drug intelligence / Profile preview

PM 2040

Development stage: Unknown
Lead developer: Phytomyco Research
Modality: Small Molecules
Administration: Oral

Overview

PM 2040 is a natural product-based nutraceutical developed by Phytomyco Research for the treatment and management of diabetes. It is an AYUSH-licensed drug in India, signifying its origin from traditional medicinal practices and its compliance with specific regulatory standards for herbal products. The drug is part of Phytomyco's nutraceutical development pipeline, which focuses on leveraging plant-derived compounds for therapeutic applications.

Beyond the preview

Go deeper on PM 2040.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PM 2040.

Explore the full profile